Opinion|Videos|November 14, 2024
Key Considerations for Genetic Testing Selection in Pediatric Patients with Epilepsy
Author(s)John Michael Schreiber, MD
Key Takeaways
- Genetic testing is vital for diagnosing epilepsy with a suspected genetic basis, especially in early-onset or treatment-resistant cases.
- Pediatric genetic test selection considers age, clinical presentation, and family history, ensuring appropriate test choice.
John Michael Schreiber, MD, expands on the role of genetic testing in identifying and diagnosing epilepsy, discussing when it is clinically indicated and who should receive it, while also addressing key considerations for selecting tests for pediatric patients based on individual presentations and clinical factors, and outlining how to choose the best testing options while recognizing potential barriers and expectations for health care providers, caregivers, and patients before and after testing.
Advertisement
Episodes in this series
- Please expand on the role of genetic testing in epilepsy identification and diagnosis.
- When is genetic testing clinically indicated, and who is best suited to receive genetic testing?
- Please discuss key considerations when selecting genetic tests for pediatric patients with epilepsy.
- How does a patient’s presentation and other clinical factors influence your decision-making?
- Please outline how you choose the best testing option for patients. What, if any, barriers exist?
- What should HCPs, caregivers, and patients expect before and after the test?
Advertisement
Related to this article
An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
The CHMP recommended approval of gefurulimab (Klygefa), a weekly self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
2
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
5